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Background
To assess the safety and immunogenicity of recombinant
HIV vaccines of DNA and replicating competent Tiantan
vaccinia (rTV)vector, the small pox vaccine used in China.
Methods
HIV-1 CN54 gag, pol and env genes were constructed into
DNA and rTV vectors. 48 healthy participants were either
inoculated with rTV (5 × 104 pfu, skin scratches) or DNA
vaccine (2 mg, 4 mg, i.m.) alone, in combination, or
placed on the placebo. The participants were monitored
up to 36 weeks for clinical symptoms and laboratory tests.
Vaccine induced immunogenicity were measured by ELIs-
pot, ICS, and antibody assays.
Results
Typical skin reaction in all rTV vaccinated 24 subjects,
enlargement of the lymph nodes under the same arm
receiving rTV (12 cases) and slight fever (37.2 for 1 day, 1
case) were observed. No severe adverse events related to
the vaccines were found. In rTV single vaccination group,
positive IFN-g ELIspot was detected only in 6 of 7 vaccinia
naïve subjects. In DNA/rTV group, T cell responses were
detected in 15/16 (IFN-g ELIspot) and 16/16 (ICS) of vac-
cinia naïve and 5/6 (IFN-g Elispot) and 5/6 (ICS) of vac-
cinia experienced. The responses of CD4 cells were higher
than those of CD8 cells (100% versus 44%) and respon-
sive rates to IL-2 and IFN-g were similar. HIV-1 gag and
env antibodies were detected only in the DNA priming
and rTV boost groups and mainly among vaccinia naïve
people (13/16 in naïve and 1/6 in experienced). Both T
cell and antibody responses maintain by the end of the
study at week 36.
Conclusion
The vaccines are well tolerated and safe. It can stimulate
HIV-1 specific T cell response in a single rTV vaccination
and both T cell and antibody responses in DNA prime rTV
boost. The vaccines are currently moving to phase II clin-
ical trial in China.
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